Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Conditional restriction
WADA 2026: intravenous administration as an S5 plasma expander is prohibited at all times and specified. The route qualification is retained in the future 2027 List. [1] [2]
2026 and 2027 List, S5, printed p.12; introductory definitions p.3 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Medical and pharmacological context
The reviewed US intravenous mannitol label covers reduction of raised intracranial or intraocular pressure and treatment of cerebral edema. It is an osmotic diuretic. [3]
- The cited country-specific product information does not establish worldwide authorization or current supply.
Health concerns
The intravenous label warns about kidney failure, central nervous system toxicity, hypersensitivity and fluid or electrolyte disturbances. Risks and indications depend on the formulation and route. [3]
- Selected warnings, not a complete contraindication or interaction list. Patient-label evidence does not establish athlete safety.
Additional anti-doping conditions
When a prohibited diuretic or masking agent is detected with formoterol, salbutamol, cathine, ephedrine, methylephedrine or pseudoephedrine, S5 has an additional TUE requirement even below the usual threshold. The note expressly excludes qualifying carbonic-anhydrase-inhibitor eye administration and local dental felypressin. It is not a dosing or test-clearance rule. [1] [2]
- A prescription or medical indication is not itself a TUE approval.
Route and procedure matter
The S5 entry is intravenous-specific. Separately, M2 governs IV procedures, including volume and medical-setting exceptions. A permitted procedure does not automatically authorize a prohibited substance. Ordinary oral exposure is not intravenous plasma expansion. [1] [2]
- Other ingredients and other applicable rules still require checking.
Inhaled mannitol
WADA states that inhaled mannitol is permitted. The reviewed US Bronchitol label concerns add-on maintenance treatment to improve lung function in adults with cystic fibrosis; severe bronchospasm is a labeled risk. [4] [5]
- Permission under the sport rule is not a claim of medical safety or suitability.
What remains uncertain
- Educational synthesis only; not individualized medical advice, a TUE decision or a sanction prediction.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Introduction p.3 · S5 p.12 · M2.2 p.13
- WADA 2027 Prohibited List, 4 November revision ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected · FUTURE 2027 SOURCE
Introduction p.3 · S5 p.12 · M2.2 p.13
- Mannitol injection prescribing information, DailyMed ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Indications; clinical pharmacology or SmPC sections 4.1 and 5.1 · Warnings, precautions and adverse reactions
- WADA Prohibited List and FAQs ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
FAQ: eye drops containing beta-blockers · FAQ: intravenous iron dextran · WADA mannitol FAQ; Bronchitol indication and bronchospasm warning
- Bronchitol (mannitol inhalation powder) FDA-hosted prescribing information ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
WADA mannitol FAQ; Bronchitol indication and bronchospasm warning
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.